Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Kelley E. McQueeney"'
Publikováno v:
Cancer Research. 83:4309-4309
The use of imperfect models and ex vivo culture systems to try to predict patient drug response represents an enormous bottle neck in cancer treatment. Nonetheless, determining how effective an approved drug will be for an individual cancer patient,
Autor:
Brittany Meisenheimer, Ha V. Vo, Kelley E. McQueeney, Aisha L. Saldanha, Carina Feeney, Courtney H. Qi, Swati Narayan, Jennifer D. Curtis, Marisa R. Nucci, Anthony Letai, Cloud P. Paweletz, Joyce F. Liu, Ursula A. Matulonis, Elena Ivanova
Publikováno v:
Cancer Research. 83:162-162
Background N of 1 treatment paradigms represent the pinnacle of personalized medicine in which a patient’s tumors are profiled to guide treatment. Low-grade serous ovarian cancer (LGSC) is a distinct subtype of ovarian cancer, comprising ~10% of se
Autor:
David T. Scadden, Kristopher A. Sarosiek, Isaac S. Harris, Joan S. Brugge, Vinícius Guimarães Ferreira, Danielle S. Potter, Veerle W. Daniels, Salma Parvin, Geoffrey Fell, Jennifer E. Endress, Patrick Bhola, Jason J. Zoeller, Rajat M. Gupta, Johan Spetz, Nick van Gastel, Emanuel Carrilho, Kelley E. McQueeney, Anthony Letai, Binyam Yilma
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Sci Signal
Universidade de São Paulo (USP)
instacron:USP
Sci Signal
Cancer cells have differential metabolic dependencies compared to their non-malignant counterparts. However, few metabolism-targeting compounds have been successful in clinical trials. Here, we investigated the metabolic vulnerabilities of triple-neg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89553705ba3fc5934a2d914c7b0c87f3
Autor:
Isabella K. Blanco, John H. Bushweller, Elizabeth R. Sharlow, Peter Wipf, Kelley E. McQueeney, Ettore J. Rastelli, Mateusz P. Czub, Adam Boulton, Wladek Minor, Taber S. Maskrey, Nikhil R. Tasker, John S. Lazo
Publikováno v:
Mol Pharmacol
Protein tyrosine phosphatase (PTP) 4A3 is frequently overexpressed in human solid tumors and hematologic malignancies and is associated with tumor cell invasion, metastasis, and a poor patient prognosis. Several potent, selective, and allosteric smal
Autor:
Kimmie Ng, Alaba Sotayo, Patrick Bhola, Elizaveta Lavrova, Kelley E. McQueeney, Otari Chipashvili, Ewa Sicinska, Timothy Hagan, Jennifer L. Guerriero, Eman Ahmed, Andrew J. Aguirre, Jeremy Ryan, David Cocozziello, Emily Su, Jean J. Zhao, Anthony Letai, James M. Cleary, Marissa S. Pioso, Jing Ni
Publikováno v:
Sci Signal
Despite decades of effort, the sensitivity of patient tumors to individual drugs is often not predictable on the basis of molecular markers alone. Therefore, unbiased, high-throughput approaches to match patient tumors to effective drugs, without req
Autor:
John S. Lazo, Heather L. Struckman, Elizabeth R. Sharlow, Isabella K. Blanco, Jennifer Ahn, Kelley E. McQueeney, Joseph M. Salamoun, Peter Wipf, Paula Pekic
Publikováno v:
The FASEB Journal. 32:5661-5673
Dysregulation of the tightly controlled protein phosphorylation networks that govern cellular behavior causes cancer. The membrane-associated, intracellular protein tyrosine phosphatase PTP4A3 is overexpressed in human colorectal cancer and contribut
Publikováno v:
The Journal of Eukaryotic Microbiology
Trypanosoma brucei is the causative agent of diseases that affect 30,000–50,000 people annually. Trypanosoma brucei harbors unique organelles named glycosomes that are essential to parasite survival, which requires growth under fluctuating environm
Autor:
John S. Lazo, Nektarios Barabutis, Peter Wipf, Kelley E. McQueeney, Joseph M. Salamoun, John D. Catravas
Publikováno v:
The FASEB Journal. 32
Autor:
Elizabeth R. Sharlow, James C. Burnett, John S. Lazo, Robert Cornelison, Nektarios Barabutis, John D. Catravas, Joseph M. Salamoun, Zhong Yin Zhang, Danielle C. Llaneza, Yunpeng Bai, Sophie L. Lewandowski, Paula Pekic, Peter Wipf, Kelley E. McQueeney, Charles N. Landen
Publikováno v:
Oncotarget
// Kelley E. McQueeney 1 , Joseph M. Salamoun 2 , James C. Burnett 2 , Nektarios Barabutis 3 , Paula Pekic 1 , Sophie L. Lewandowski 1 , Danielle C. Llaneza 4 , Robert Cornelison 4 , Yunpeng Bai 5 , Zhong-Yin Zhang 5 , John D. Catravas 3 , Charles N.
Publikováno v:
SLAS discovery : advancing life sciences RD. 22(9)
The drug discovery landscape is littered with promising therapeutic targets that have been abandoned because of insufficient validation, historical screening failures, and inferior chemotypes. Molecular targets once labeled as "undruggable" or "intra